

Maximizing IP Value: Strategize Now to Win Later



As part of Goodwin's exclusive programming during the BIO International Convention in Boston, we invite you to join us for a focused discussion on how biotech and pharma companies can protect and maximize the value of their intellectual property. In a time when innovation is critical and IP disputes are on the rise, getting ahead of IP strategy is more important than ever.

Through a candid conversation with leading litigators and experts, we'll examine real-world disputes, lessons learned, and practical strategies to preserve competitive edge and prepare for what's ahead.

Please RSVP [here](#) and see below for more details!

Date & Time: Wednesday, June 18 from 10:00 AM - 11:30 AM ET

Location: Goodwin's Boston Office, 100 Northern Avenue, Boston, MA 02210

10:00 - 10:30 PM | Registration

10:30 PM - 11:30 PM | Unlocking the Long-Term Value of Your IP - Lessons from the Trenches

- Elaine Blais, Partner, Goodwin
- Robert Frederickson, Partner, Goodwin
- Emily Rapalino, Partner, Goodwin
- Daryl Wiesen, Partner, Goodwin
- Leda Trivinos, Senior Partner, Intellectual Property, Flagship Pioneering

Biosimilars Webinar: Prosecution and Litigation Trends and Takeaways from BPCIA Litigation



[Michael Siekman](#), [Huiya Wu](#), [Allegra Padula](#), and [Riley](#)

[Wyberg](#) will present their data-driven analyses of trends in BPCIA litigation and relevant takeaways.

With 10 years of litigation since the first BPCIA complaint on NEUPOGEN (filgrastim) was filed in 2014, trends are becoming apparent that should cause all biopharma companies to reassess how they protect biologics and plan for biosimilar launch.

Webinar Highlights:

- **Patents Being Asserted:** Learn which types of patents are being asserted to block biosimilar competition, how that has changed over time, differences for protein and antibody products, when those patents are being filed during drug development, and differences among Reference Product Sponsors.
- **Trends in BPCIA Litigation:** Learn how often and how much of aBLAs are being produced during the Patent Dance, which Biosimilar Manufacturers are producing them, how much the parties dance and who is engaging in the Patent Dance, when cases are settling, and how many asserted patents are carrying through to a final judgment.
- **Real-World Insights:** We will share practical recommendations for biologics and biosimilars companies based upon on our analysis and our experience with the BPCIA.

Please [RSVP](#) to confirm your attendance.